Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

livanova plc - LIVN

LIVN

Close Chg Chg %
65.03 1.53 2.35%

Closed Market

66.56

+1.53 (2.35%)

Volume: 578.05K

Last Updated:

Feb 6, 2026, 4:00 PM EDT

Trade Now

Company Overview: livanova plc - LIVN

LIVN Key Data

Open

$65.45

 Day Range

64.98 - 66.92

52 Week Range

32.48 - 67.92

 Market Cap

$3.57B

Shares Outstanding

54.61M

 Public Float

54.43M

Beta

0.97

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.00

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

616.11K

  

LIVN Performance

1 Week
 
 1.29%
 
1 Month
 
 3.34%
 
3 Months
 
 31.93%
 
1 Year
 
 39.19%
 
5 Years
 
 -1.58%
 

LIVN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About livanova plc - LIVN

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.

LIVN At a Glance

LivaNova Plc
20 Eastbourne Terrace
London, Greater London W2 6LG
Phone 44-203-325-0660 Revenue 1.25B
Industry Medical Specialties Net Income 63.23M
Sector Health Technology 2024 Sales Growth 8.66%
Fiscal Year-end 12 / 2025 Employees 2,900
View SEC Filings

LIVN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 39.967
Price to Sales Ratio 2.016
Price to Book Ratio 1.906
Price to Cash Flow Ratio 13.81
Enterprise Value to EBITDA 11.453
Enterprise Value to Sales 1.979
Total Debt to Enterprise Value 0.273

LIVN Efficiency

Revenue/Employee 432,219.655
Income Per Employee 21,804.828
Receivables Turnover 6.489
Total Asset Turnover 0.508

LIVN Liquidity

Current Ratio 2.875
Quick Ratio 2.498
Cash Ratio 1.845

LIVN Profitability

Gross Margin 69.583
Operating Margin 13.199
Pretax Margin 7.045
Net Margin 5.045
Return on Assets 2.562
Return on Equity 4.868
Return on Total Capital 3.166
Return on Invested Capital 3.327

LIVN Capital Structure

Total Debt to Total Equity 51.261
Total Debt to Total Capital 33.889
Total Debt to Total Assets 27.002
Long-Term Debt to Equity 44.668
Long-Term Debt to Total Capital 29.53
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Livanova Plc - LIVN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
1.04B 1.02B 1.15B 1.25B
Sales Growth
+10.82% -1.31% +12.89% +8.66%
Cost of Goods Sold (COGS) incl D&A
328.81M 304.08M 368.10M 381.26M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
67.99M 57.80M 60.86M 51.14M
Depreciation
41.47M 32.60M 35.38M 33.93M
Amortization of Intangibles
26.52M 25.20M 25.47M 17.21M
COGS Growth
-5.18% -7.52% +21.05% +3.58%
Gross Income
706.56M 717.73M 785.45M 872.17M
Gross Income Growth
+20.27% +1.58% +9.44% +11.04%
Gross Profit Margin
+68.24% +70.24% +68.09% +69.58%
2021 2022 2023 2024 5-year trend
SG&A Expense
641.13M 595.40M 684.15M 687.09M
Research & Development
166.81M 136.42M 166.02M 180.51M
Other SG&A
474.31M 458.98M 518.13M 506.58M
SGA Growth
+10.60% -7.13% +14.90% +0.43%
Other Operating Expense
1.78M 616.00K 2.35M 19.64M
Unusual Expense
130.97M 145.01M 144.54M 40.35M
EBIT after Unusual Expense
(67.31M) (23.30M) (45.59M) 125.09M
Non Operating Income/Expense
(7.01M) (3.65M) 23.75M 26.29M
Non-Operating Interest Income
435.00K 4.70M 22.01M 30.07M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
50.15M 48.20M 59.39M 63.07M
Interest Expense Growth
+23.15% -3.89% +23.21% +6.20%
Gross Interest Expense
50.15M 48.20M 59.39M 63.07M
Interest Capitalized
- - - -
-
Pretax Income
(124.47M) (75.14M) (81.23M) 88.31M
Pretax Income Growth
+63.81% +39.63% -8.10% +208.72%
Pretax Margin
-12.02% -7.35% -7.04% +7.05%
Income Tax
11.20M 11.05M (98.88M) 25.06M
Income Tax - Current - Domestic
4.05M 4.86M 4.60M 4.41M
Income Tax - Current - Foreign
4.30M 4.78M 10.95M 13.85M
Income Tax - Deferred - Domestic
- - - 808.00K
-
Income Tax - Deferred - Foreign
2.85M 1.41M (114.43M) 5.99M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(135.82M) (86.25M) 17.55M 63.23M
Minority Interest Expense
- - - -
-
Net Income
(135.82M) (86.25M) 17.55M 63.23M
Net Income Growth
+60.46% +36.50% +120.34% +260.39%
Net Margin Growth
-13.12% -8.44% +1.52% +5.04%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(135.82M) (86.25M) 17.55M 63.23M
Preferred Dividends
- - - -
-
Net Income Available to Common
(135.82M) (86.25M) 17.55M 63.23M
EPS (Basic)
-2.6824 -1.6129 0.3253 1.1658
EPS (Basic) Growth
+62.39% +39.87% +120.17% +258.38%
Basic Shares Outstanding
50.63M 53.47M 53.94M 54.24M
EPS (Diluted)
-2.6824 -1.6129 0.3237 1.1587
EPS (Diluted) Growth
+62.39% +39.87% +120.07% +257.95%
Diluted Shares Outstanding
50.63M 53.47M 54.21M 54.57M
EBITDA
131.64M 179.51M 159.81M 216.58M
EBITDA Growth
+47.75% +36.36% -10.97% +35.53%
EBITDA Margin
+12.71% +17.57% +13.85% +17.28%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 73.10
Number of Ratings 11 Current Quarters Estimate 0.901
FY Report Date 03 / 2026 Current Year's Estimate 4.132
Last Quarter’s Earnings 0.805 Median PE on CY Estimate N/A
Year Ago Earnings 3.862 Next Fiscal Year Estimate 4.474
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 9 9 10 10
Mean Estimate 0.90 1.11 4.13 4.47
High Estimates 0.97 1.14 4.25 4.73
Low Estimate 0.80 0.99 4.02 4.38
Coefficient of Variance 5.83 4.18 1.57 2.50

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 6
OVERWEIGHT 1 1 1
HOLD 3 3 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Livanova Plc - LIVN

Date Name Shares Transaction Value
Sep 18, 2025 Franco Poletti President, Cardiopulmonary 8,576 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Sep 18, 2025 Franco Poletti President, Cardiopulmonary 8,299 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $55.43 per share 460,013.57
Sep 18, 2025 Franco Poletti President, Cardiopulmonary 1,932 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Sep 18, 2025 Donald J. Zurbay Director 2,560 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Stephanie Bolton President, Global Epilepsy N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Michael David Hutchinson Chief Legal Officer 6,686 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Stephanie Bolton President, Global Epilepsy 15,385 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Stephanie Bolton President, Global Epilepsy 3,513 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Stephanie Bolton President, Global Epilepsy 3,513 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Stephanie Bolton President, Global Epilepsy 7,027 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Stephanie Bolton President, Global Epilepsy N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Stephanie Bolton President, Global Epilepsy N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Vladimir A. Makatsaria Chief Executive Officer; Director 76,927 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Stephanie Bolton President, Global Epilepsy 2,659 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Stephanie Bolton President, Global Epilepsy 457 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Stephanie Bolton President, Global Epilepsy N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 Stephanie Bolton President, Global Epilepsy 12,751 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $39.13 per share 498,946.63
Apr 2, 2025 Stephanie Bolton President, Global Epilepsy 15,586 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 William A. Kozy Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 2, 2025 William A. Kozy Director 28,308 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $39.13 per share 1,107,692.04

Livanova Plc in the News